Amgen signs $800 million deal with IBM
This article was originally published in Scrip
Amgenhas signed a five-year $500 million service agreement withIBM. IBMwill supply the biotech company with information systems infrastructure services, including electronic messaging systems, networks, helpdesk support for end users, physical information technology support, server hosting applications and information systems hardware. It will also develop methods, processes and technologies being used to provide information systems infrastructure services. Amgen may choose to extend the deal for a further three years, bringing the total amount payable to IBM to $800 million.
You may also be interested in...
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.
Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.